PainChek has seen significant growth over the first quarter of 2024 with 90,000 contracted licences across almost 1,600 aged care facilities in four countries, representing a 40% increase compared to the year prior.
Global aged care snapshot
- 90,000 contracted licences, a 40% increase on the year prior.
- Over 5,000,000 cumulative PainChek® clinical assessments conducted as of 31 March 2024, an increase of 128% over the previous year, reflecting continued strong growth in clinical use and implementation.
- 88% retention rate for PainChek® customers in the March quarter.
“We are delighted to confirm continued strong business growth achieving 90,000 global licences that is 40% growth on previous year with strong pipeline opportunities across all four existing countries and market segments.
Significantly 30% of all licences are now from overseas clients, including 30,000 from the large UK market confirming the international application of the PainChek® Adult technology. These are key commercial milestones and positive evidence of PainChek’s capability to enter overseas markets as we progress towards FDA clearance and US market entry in 2024.”
– Philip Daffas, PainChek CEO & Managing Director
Australia and New Zealand
In Australia and New Zealand, PainChek has ~60,000 licences across ~790 facilities, representing a 21% increase over the year prior. Of these licences, over half are contracted by clients with more than 1,000 beds, with PainChek well positioned to support them on their digital transformation journey. These clients include:
- Bolton Clarke – 8,000+ beds across 85 homes
- Uniting Care Queensland – 3,750 beds across 46 homes
- BlueCross – 2,800 beds across 32 homes
- Baptist Care NSW/ACT – 2,000+ beds across 20 homes
- Ozcare – 2,000+ beds across 17 homes
- Anglicare NSW – 2,000+ beds across 21 homes
- Frank Whiddon Group – 1,750 beds across 17 homes
Notable updates from the quarter include:
- Established an agreement to implement PainChek® at WentWest PHN, covering 700 beds.
- Extended the existing agreement across newly acquired Ozcare and Goodwin Homes.
- Commenced implementation at the Nurse Maude Hospital (NZ).
UK
PainChek has grown significantly in the UK with over 30,000 contracted licences across 870 aged care facilities, a 101% year on year increase and 21% in the quarter. This includes 20 contracts signed in the quarter, adding over 5,000 licences. This growth has been driven by the positive clinical outcomes PainChek® continually delivers in aged care, along with the support of government and provider-funded projects and pilots.
Some of PainChek’s larger UK clients include:
- Exemplar Healthcare – 1,800 beds across 40 homes
- We Care Group – 1,400 beds across 28 homes
- Orchard Care Homes – 1,300 beds across 23 homes
- Greensleeves Trust – 1,300 beds across some 28 homes
- Harbour Healthcare – 1,200 beds across 22 homes
- Dovehaven Care Homes – 1,000 beds across 21 homes
Nourish Care, a leading provider of care management software in the UK, has recently rolled out a channel partnership with PainChek. This partnership will enable Nourish Care to resell PainChek’s digital pain assessment app to its client base, which currently supports over 320,000 people receiving care across multiple care settings including residential, disability, and home care.
The Department of Health and Social Care (DHSC) has partnered with NHS England to launch the Adult Social Care Technology Fund (ASCTF). This initiative aims to identify care-focused technology with the potential for wider rollout within England. The Bedford, Luton and Milton Keynes’ Integrated Care System (BLMK ICS) recently applied for the latest wave of the ASCTF and was successful among over 200 other applications for social care technologies across the UK. BLMK ICS will receive funding for an initial 1,000 PainChek® licences. The University of Hertfordshire and Health Innovation East will independently evaluate the benefits of using PainChek®. If PainChek® proves successful during the 15-month period of its adoption across BLMK ICS, the DHSC could support a national rollout of PainChek® across England.
In addition, new training and customer success managers have joined the PainChek team to support implementations in the UK. Training is through a combination of ‘train the trainer’ for large groups, on site and online, supported by online training tools and a support desk.
North America
In North America, we are pleased to continue growing our partnership with PointClickCare (PCC), the leading cloud-based healthcare software provider for the long-term and post-acute care (LTPAC) and senior care industries. PainChek® has already successfully integrated with PCC, and that integration is being used by several Canadian customers including Sherwood Care and St. Michael’s Health Group.
PainChek was also represented at the annual PointClickCare Summit in New Orleans in February 2024, which hosted over 3,200 PCC partners, clients and prospects.
In addition, PainChek’s US Validation Study is progressing positively, and data collection has been completed at four clinical sites in Iowa. Final monitoring of these sites and data analysis by the Clinical Research Organisation (CRO) is now underway. The resulting Clinical Investigation Report will support PainChek’s FDA de novo application, which is planned to be submitted later this year.
Continued progress for PainChek® Infant
We have taken on board recent consumer market research feedback and updated the PainChek® Infant app in preparation for an initial limited release in Australia in the coming months.
PainChek® Infant’s facial AI uses camera technology to scan and analyse infant facial features that are indicative of pain. In addition, newly-developed vocalisation AI utilises microphone-based technology to analyse the infant’s voice to differentiate between a cry of pain versus a cry of no pain. The following graphic provides an overview of the combined capability:
PainChek published in reviews, further clinical research underway
There are two Hollywood Private Hospital (WA) based research projects currently underway to assess the effectiveness of PainChek® in improving pain assessment for hospitalised older adults.
We are also conducting a “Pain Profiling” research initiative to build PainChek®’s capability to profile people’s pain features, as a basis for more targeted and individualised pain treatment within the broader population.
In addition, PainChek® Adult and Infant have been cited in several recent reviews:
- Lindroth H, Nalaie K, Raghu R, Ayala IN, Busch C, Bhattacharyya A, Moreno Franco P, Diedrich DA, Pickering BW, Herasevich V. Applied Artificial Intelligence in Healthcare: A Review of Computer Vision Technology Application in Hospital Settings. Journal of Imaging. 2024 Mar 28;10(4):81. https://www.mdpi.com/2313- 433X/10/4/81
- El-Tallawy SN, Pergolizzi JV, Vasiliu-Feltes I, Ahmed RS, LeQuang JK, El-Tallawy HN, Varrassi G, Nagiub MS. Incorporation of “Artificial Intelligence” for Objective Pain Assessment: A Comprehensive Review. Pain and Therapy. 2024 Mar 2:1-25. https://link.springer.com/article/10.1007/s40122-024-00584-8
- Sabater-Gárriz Á, Molina-Mula J, Montoya P, Riquelme I. Pain assessment tools in adults with communication disorders: systematic review and meta-analysis. BMC neurology. 2024 Feb 17;24(1):66. https://link.springer.com/article/10.1186/s12883-024-03539-w
To learn more about how PainChek® could enable best-practice pain management within your organisation, book a one-on-one session with a member of our team.
